WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

Phase 2

Terminated

Conditions: Previously Treated Myelodysplastic Syndromes

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid

First Posted Date: 2013-07-18

Last Posted Date: 2024-10-17

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 12

Registration Number: NCT01902381

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Recruiting

Conditions: Multiple Myeloma
Germ Cell Neoplasms
Acute Myelogenous Leukemia
Non-Hodgkin's Lymphoma
Myelodysplastic Syndromes
Hodgkin's Disease
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Immunodeficiency Diseases

First Posted Date: 2013-07-01

Last Posted Date: 2024-06-12

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2000

Registration Number: NCT01890486

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair

Not Applicable

Completed

Conditions: Ventral Hernia

Interventions: Device: SPY - Unblinded use of SPY Elite
Device: Control - Blinded use of SPY Elite

First Posted Date: 2013-06-26

Last Posted Date: 2022-04-21

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 115

Registration Number: NCT01886963

Locations: 🇺🇸
Atrium Health - Carolinas Medical Center, Charlotte, North Carolina, United States

Improving Resection Rates Among African Americans With NSCLC

Not Applicable

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Other: Intervention Arm
Other: Usual Care

First Posted Date: 2013-06-25

Last Posted Date: 2020-05-12

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 248

Registration Number: NCT01885455

Locations: 🇺🇸
Beebe Healthcare Tunnell Cancer Center, Lewes, Delaware, United States
🇺🇸
Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
Saint Joseph's/Candler Hospital, Savannah, Georgia, United States

and more 7 locations

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Promyelocytic Leukemia (M3)
Childhood Acute Promyelocytic Leukemia (M3)
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia

First Posted Date: 2013-06-05

Last Posted Date: 2018-03-02

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT01869803

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Mast Cell Leukemia
Adult Acute Myeloid Leukemia With Del(5q)
Myeloid/NK-cell Acute Leukemia
Acute Undifferentiated Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Untreated Adult Acute Lymphoblastic Leukemia

Interventions: Procedure: bioelectric impedance analysis

First Posted Date: 2013-06-05

Last Posted Date: 2020-08-13

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 102

Registration Number: NCT01869777

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Stage II Breast Cancer
Ductal Breast Carcinoma in Situ
Lobular Breast Carcinoma in Situ
Stage IIIB Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIC Breast Cancer

Interventions: Other: placebo
Drug: omega-3 fatty acid
Other: laboratory biomarker analysis

First Posted Date: 2013-06-05

Last Posted Date: 2019-10-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 57

Registration Number: NCT01869764

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

Not Applicable

Withdrawn

Conditions: Colorectal Cancer

Interventions: Drug: Irinotecan
Radiation: CyberKnife

First Posted Date: 2013-05-07

Last Posted Date: 2024-10-04

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT01847495

Locations: 🇺🇸
Advocate Lutheran General Hospital, Park Ridge, Illinois, United States

Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study

Terminated

Conditions: Awake Endotracheal Intubation
Difficult Intubation
Airway Anesthesia

Interventions: Procedure: Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark

First Posted Date: 2013-05-07

Last Posted Date: 2017-11-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT01848548

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

Phase 2

Completed

Conditions: Total Parenteral Nutrition-induced Cholestasis

Interventions: Drug: Omegaven®

First Posted Date: 2013-05-03

Last Posted Date: 2022-11-23

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 11

Registration Number: NCT01845116

Locations: 🇺🇸
Levine Children's Hospital at Carolinas HealthCare System, Charlotte, North Carolina, United States

Home Terms & Conditions Privacy Policy